tetano
Editor, Senior Moderator
Ann Transl Med
. 2021 Aug;9(15):1261.
doi: 10.21037/atm-21-1783.
Tailoring glucocorticoids in patients with severe COVID-19: a narrative review
Ming-Hao Luo[SUP] 1 [/SUP], Yi-Qi Qian[SUP] 2 [/SUP], Dan-Lei Huang[SUP] 1 [/SUP], Jing-Chao Luo[SUP] 2 [/SUP], Ying Su[SUP] 2 [/SUP], Huan Wang[SUP] 2 [/SUP], Shen-Ji Yu[SUP] 2 [/SUP], Kai Liu[SUP] 2 [/SUP], Guo-Wei Tu[SUP] 2 [/SUP], Zhe Luo[SUP] 2 3 [/SUP]
Affiliations
Abstract
Objective: To discuss the pathogenesis of severe coronavirus disease 2019 (COVID-19) infection and the pharmacological effects of glucocorticoids (GCs) toward this infection. To review randomized controlled trials (RCTs) using GCs to treat patients with severe COVID-19, and investigate whether GC timing, dosage, or duration affect clinical outcomes. Finally. to discuss the use of biological markers, respiratory parameters, and radiological evidence to select patients for improved GC therapeutic precision.
Background: COVID-19 has become an unprecedented global challenge. As GCs have been used as key immunomodulators to treat inflammation-related diseases, they may play key roles in limiting disease progression by modulating immune responses, cytokine production, and endothelial function in patients with severe COVID-19, who often experience excessive cytokine production and endothelial and renin-angiotensin system (RAS) dysfunction. Current clinical trials have partially proven this efficacy, but GC timing, dosage, and duration vary greatly, with no unifying consensus, thereby creating confusion.
Methods: Publications through March 2021 were retrieved from the Web of Science and PubMed. Results from cited references in published articles were also included.
Conclusions: GCs play key roles in treating severe COVID-19 infections. Pharmacologically, GCs could modulate immune cells, reduce cytokine and chemokine, and improve endothelial functions in patients with severe COVID-19. Benefits of GCs have been observed in multiple clinical trials, but the timing, dosage and duration vary across studies. Tapering as an option is not widely accepted. However, early initiation of treatment, a tailored dosage with appropriate tapering may be of particular importance, but evidence is inconclusive and more investigations are needed. Biological markers, respiratory parameters, and radiological evidence could also help select patients for specific tailored treatments.
Keywords: C-reactive protein (CRP); Coronavirus disease 2019 (COVID-19); computed tomography; cytokines; glucocorticoid (GC).
. 2021 Aug;9(15):1261.
doi: 10.21037/atm-21-1783.
Tailoring glucocorticoids in patients with severe COVID-19: a narrative review
Ming-Hao Luo[SUP] 1 [/SUP], Yi-Qi Qian[SUP] 2 [/SUP], Dan-Lei Huang[SUP] 1 [/SUP], Jing-Chao Luo[SUP] 2 [/SUP], Ying Su[SUP] 2 [/SUP], Huan Wang[SUP] 2 [/SUP], Shen-Ji Yu[SUP] 2 [/SUP], Kai Liu[SUP] 2 [/SUP], Guo-Wei Tu[SUP] 2 [/SUP], Zhe Luo[SUP] 2 3 [/SUP]
Affiliations
- PMID: 34532398
- PMCID: PMC8421952
- DOI: 10.21037/atm-21-1783
Abstract
Objective: To discuss the pathogenesis of severe coronavirus disease 2019 (COVID-19) infection and the pharmacological effects of glucocorticoids (GCs) toward this infection. To review randomized controlled trials (RCTs) using GCs to treat patients with severe COVID-19, and investigate whether GC timing, dosage, or duration affect clinical outcomes. Finally. to discuss the use of biological markers, respiratory parameters, and radiological evidence to select patients for improved GC therapeutic precision.
Background: COVID-19 has become an unprecedented global challenge. As GCs have been used as key immunomodulators to treat inflammation-related diseases, they may play key roles in limiting disease progression by modulating immune responses, cytokine production, and endothelial function in patients with severe COVID-19, who often experience excessive cytokine production and endothelial and renin-angiotensin system (RAS) dysfunction. Current clinical trials have partially proven this efficacy, but GC timing, dosage, and duration vary greatly, with no unifying consensus, thereby creating confusion.
Methods: Publications through March 2021 were retrieved from the Web of Science and PubMed. Results from cited references in published articles were also included.
Conclusions: GCs play key roles in treating severe COVID-19 infections. Pharmacologically, GCs could modulate immune cells, reduce cytokine and chemokine, and improve endothelial functions in patients with severe COVID-19. Benefits of GCs have been observed in multiple clinical trials, but the timing, dosage and duration vary across studies. Tapering as an option is not widely accepted. However, early initiation of treatment, a tailored dosage with appropriate tapering may be of particular importance, but evidence is inconclusive and more investigations are needed. Biological markers, respiratory parameters, and radiological evidence could also help select patients for specific tailored treatments.
Keywords: C-reactive protein (CRP); Coronavirus disease 2019 (COVID-19); computed tomography; cytokines; glucocorticoid (GC).